GMC

Genzyme Molecular Oncology (GMC) was a biotechnology company focused on the development of novel cancer therapies, including cancer vaccines and gene therapies. The company utilized its proprietary Serial Analysis of Gene Expression (SAGE) technology to identify genetic targets for drug discovery and diagnostic applications. Its pipeline featured several immunotherapy candidates, most notably cancer vaccines targeting melanoma and other solid tumors. Originally established as a tracking stock division of Genzyme Corporation, GMC operated independently in the public markets before being reintegrated into the parent company. The company's research emphasized the identification of tumor-specific antigens and the development of delivery systems for genetic material.